114 related articles for article (PubMed ID: 12412538)
1. Labeling changes for arthritis drug.
FDA Consum; 2002; 36(5):6. PubMed ID: 12412538
[No Abstract] [Full Text] [Related]
2. Vioxx withdrawal alarms cancer prevention researchers.
Vanchieri C
J Natl Cancer Inst; 2004 Dec; 96(23):1734-5. PubMed ID: 15572751
[No Abstract] [Full Text] [Related]
3. The COX-2 inhibitors--an update.
Furberg CD
Am Heart J; 2006 Aug; 152(2):197-9. PubMed ID: 16875896
[No Abstract] [Full Text] [Related]
4. Drug safety. FDA panel urges caution on many anti-inflammatory drugs.
Couzin J
Science; 2005 Feb; 307(5713):1183-5. PubMed ID: 15731414
[No Abstract] [Full Text] [Related]
5. FDA announces changes affecting the marketing of non-steroidal anti-inflammatory drugs.
FDA Consum; 2005; 39(3):7. PubMed ID: 16127812
[No Abstract] [Full Text] [Related]
6. Celecoxib (Celebrex): 1 year later.
McMorran M; Morawiecka I
CMAJ; 2000 Apr; 162(7):1044-6, 1048-50. PubMed ID: 10763409
[No Abstract] [Full Text] [Related]
7. From the Food and Drug Administration.
Nightingale SL
JAMA; 1999 Mar; 281(9):786. PubMed ID: 10070983
[No Abstract] [Full Text] [Related]
8. Coxibs and cardiovascular risk.
Allen MJ; McLean-Veysey P; Fleming I
CMAJ; 2005 Oct; 173(8):853. PubMed ID: 16217098
[No Abstract] [Full Text] [Related]
9. Proposed NSAID package insert labeling.
Food and Drug Administration U.S. Public Health Service
J Pain Palliat Care Pharmacother; 2006; 20(1):49-55. PubMed ID: 16687359
[TBL] [Abstract][Full Text] [Related]
10. Response to Ray and colleagues: the called-for large clinical trial is already ongoing.
Peura D; Chan FK; Wilcox CM; Niculescu L; Berger M
Gastroenterology; 2008 Jan; 134(1):370-1; author reply 371. PubMed ID: 18166374
[No Abstract] [Full Text] [Related]
11. The pain game.
Wadman M
Nature; 2007 Jul; 448(7152):400-1. PubMed ID: 17653159
[No Abstract] [Full Text] [Related]
12. [Gastrointestinal complications caused by NSAIDs. Over 60% of arthrosis patients are endangered].
MMW Fortschr Med; 2003 Mar; 145(10):60. PubMed ID: 12688036
[No Abstract] [Full Text] [Related]
13. Cyclooxygenase-2 inhibitors and cardiovascular risk.
Smith ER
Can J Cardiol; 2005 Mar; 21(3):307-8. PubMed ID: 15776124
[No Abstract] [Full Text] [Related]
14. Aspirin, salicylates, and nonsteroidal anti-inflammatory drugs: new class labeling and medical practice.
Roth SH
Compr Ther; 1991 Jun; 17(6):15-21. PubMed ID: 1934983
[No Abstract] [Full Text] [Related]
15. [Financial interests characterize published reports on coxiber. Whom can we rely on?].
Håkansson J
Lakartidningen; 2002 Oct; 99(40):3930-1. PubMed ID: 12422746
[No Abstract] [Full Text] [Related]
16. Another popular painkiller gets the government's hook.
Querna E
US News World Rep; 2005 Apr; 138(14):47. PubMed ID: 15839129
[No Abstract] [Full Text] [Related]
17. [When the cardiac patient with arthritis needs aspirin and NSAID: how to protect the stomach?].
Zeidler H
MMW Fortschr Med; 2003 Jan; 145(5):8. PubMed ID: 12619198
[No Abstract] [Full Text] [Related]
18. Why don't we initiate more large simple randomized controlled trials?
Wright JM
CMAJ; 2003 Nov; 169(11):1170-1. PubMed ID: 14638653
[No Abstract] [Full Text] [Related]
19. Challenges and opportunities in animal drug development: a regulatory perspective.
Lathers CM
Nat Rev Drug Discov; 2003 Nov; 2(11):915-8. PubMed ID: 14560318
[No Abstract] [Full Text] [Related]
20. Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level.
Varas-Lorenzo C; Maguire A; Castellsague J; Perez-Gutthann S
Pharmacoepidemiol Drug Saf; 2007 Apr; 16(4):366-76. PubMed ID: 16897817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
